OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
复制标题
DOI：
10.1093/annonc/mdz012
复制
发表时间：
2019-04-01
影响因子：
50.5
通讯作者：
Domchek, S. M.
中科院分区：
文献类型：
--
作者：
Robson, M. E.;Tung, N.;Domchek, S. M.
背景：在 OlympiAD 研究中，对于种系 BRCA1 和/或 BRCA2 突变 (BRCAm) 和人表皮生长因子受体 2 (HER2) 阴性转移性乳腺癌 (mBC) 患者，与医生选择的化疗 (TPC) 相比，奥拉帕尼可改善无进展生存期。我们现在报告计划的最终总生存 (OS) 结果，并描述最常见的不良事件 (AE)，以更好地了解奥拉帕尼在该人群中的耐受性。 患者和方法：OlympiAD，一项 III 期、随机、对照、开放标签研究 (NCT02000622)，纳入了接受过治疗的种系 BRCAm 和 HER2 阴性 mBC 患者
Background: In the OlympiAD study, olaparib was shown to improve progression-free survival compared with chemotherapy treatment of physician's choice (TPC) in patients with a germline BRCA1 and/or BRCA2 mutation (BRCAm) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). We now report the planned final overall survival (OS) results, and describe the most common adverse events (AEs) to better understand olaparib tolerability in this population.Patients and methods: OlympiAD, a Phase III, randomized, controlled, open-label study (NCT02000622), enrolled patients with a germline BRCAm and HER2-negative mBC who had received